Last reviewed · How we verify

NCT04832659: ABC Quit

Assessment of Biomarkers in Children to Help Parents Quit Tobacco

Active, enrolled NA Last updated 9 October 2025
What this trial tests

NA trial testing CEASE in Tobacco Dependence in 865 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
20 January 2023
Primary endpoint
28 February 2026
28 February 2026

Quick facts

Lead sponsorMassachusetts General Hospital
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment865
Start date20 January 2023
Primary completion28 February 2026
Estimated completion28 February 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Tobacco Dependence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial will test whether adding biomarker measurement and informed outreach for tobacco smoke exposure as part of routine practice increases identification and improves treatment, effectiveness, and sustainability of a parental tobacco control intervention that will be integrated into pediatric practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Tobacco Dependence

Currently open trials in the same condition.

Other Massachusetts General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04832659.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing